


**Up to 1/3 of patients on antiplatelet medications may not receive the expected platelet inhibiting effect.<sup>1</sup>**

Patients with inadequate response to their antiplatelet medications may be at significantly greater risk of myocardial infarction, stent thrombosis and death.<sup>2-5</sup>

The VerifyNow **PRU**Test is a whole blood test to measure the level of platelet P2Y12 receptor blockade.

Some antiplatelet medications [e.g. Plavix<sup>®</sup> (clopidogrel) and Effient<sup>®</sup> (prasugrel)] are designed to specifically block the P2Y12 receptor to reduce the risk of ischemic events.



**What is Reported?**

The lab report may look similar to the following:

\*\*\*\*\*

<b>Patient Example</b>			<b>(off drug)</b>
<b>PRU</b> Test Results	<b>Patient A</b>	<b>Units</b>	<b>Reference Range</b>
P2Y12 Reaction Units	132	PRU	180-376


Values less than 180 PRU suggests evidence of a P2Y12 inhibitor effect.

\*\*\*\*\*

# Interventional Procedure Application

Numerous factors may cause inadequate response,<sup>7</sup> including:

- Drug Interactions (e.g. proton pump inhibitors)
- Genetic differences
- Pre-existing health conditions (e.g. diabetes)
- Non-compliance



# Pre-Surgical Application

- Studies show that there is patient variability in response to P2Y12 inhibitors<sup>9</sup>.
- Patients that have been administered P2Y12 inhibitors such as clopidogrel and prasugrel are at risk of perioperative bleeding.
- It has been recommended to discontinue P2Y12 inhibitors for 5–7 days prior to surgery<sup>10</sup> for platelet function to be restored<sup>11</sup>, however, 2012 STS Guidelines<sup>12</sup> recommend using platelet function testing to aid in timing of surgery, instead of arbitrarily waiting a pre-specified period of time.

## Conditions that May Affect Test Results:

- Patient's exposure to GP IIb/IIIa inhibitors within 48 hours of eptifibatide (Integrilin<sup>®</sup>), or 14 days of abciximab (ReoPro<sup>®</sup>).
- Improper sample collection (platelet activation).

VerifyNow PRU<sup>®</sup>Test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. Please refer to Effient<sup>®</sup> Prescribing Information. Daiichi Sankyo, Inc and Eli Lilly and Company. Please refer to Plavix Prescribing Information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.



For more details, see the VerifyNow Test package insert.

<sup>1</sup> Dupont AG, et al. Thromb Res 2009 May 124(1):6-13. <sup>2</sup> Patti G, et al. J Am Coll Cardiol 2008 52:1128-33. <sup>3</sup> Marcucci R, et al. Circulation 2009 119(2):237-42. <sup>4</sup> Cuisset T, et al. Am J Cardiol 2008 Jun 15 101(12):1700-3. <sup>5</sup> Price, MJ, et al. Eur Heart J 2008 Apr 29(8):992-1000. <sup>6</sup> VerifyNow PRU<sup>®</sup>Test [package insert]. San Diego, CA: Accriva Diagnostics; 2016 <sup>7</sup> Maree A, et al. Circulation 2007 115:2196-2207. <sup>8</sup> Price MJ, et al. J Am Coll Cardiol 2012 59:2338-43. <sup>9</sup> Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel. June 26, 2007. <sup>10</sup> Husted S et al. Eur Heart J. 2006 27:1038 -1047. <sup>11</sup> Brilinta (ticagrelor) tablets prescribing information. AstraZeneca group of companies. July 20, 2011. <sup>12</sup> 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients having Cardiac and Noncardiac Operations. © 2102 by the Society of Thoracic Surgeons. Published by Elsevier Inc.